AI Therapists: A New Frontier for Investors?

Artificial intelligence is quietly becoming one of the fastest-growing segments of digital healthcare. In mental health alone, the global AI-driven therapy and mental-health market is estimated at roughly $1.7–$2 billion in 2025 and could reach $9–12 billion within the next decade, implying growth rates above 20% annually.

That kind of growth suggests the sector is still in the early-to-middle innings, not saturation.

The trend is driven by a simple economic reality: the world has a severe shortage of trained therapists. AI chatbots and digital therapy tools can provide 24-hour emotional support, CBT-style coaching, and early mental-health screening, often at a fraction of the cost of traditional therapy. Meanwhile, adoption is already spreading—surveys show millions of people, especially younger users, are turning to AI for mental-health advice.

For investors, this opens an interesting niche. Microcap companies rarely compete with tech giants in core AI infrastructure—but they can build specialized applications, such as therapy platforms, AI diagnostic tools, or behavioral-health analytics. Early players include startups like Woebot, Wysa, and Marigold Health.

However, risks remain. Regulation is emerging and some jurisdictions are already restricting AI-only therapy services.

The bottom line: AI therapy looks less like a fad and more like a structural healthcare trend. For microcap investors, the opportunity likely lies not in the big AI platforms—but in small companies building the specialized tools riding on top of them.